70
Participants
Start Date
September 20, 2018
Primary Completion Date
August 13, 2020
Study Completion Date
November 25, 2020
mavrilimumab
1 mL of 150 mg in a pre-filled syringe
placebo
1 mL of placebo in a pre-filled syringe
prednisone
Prednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)
Site 1201, Ljubljana
Site 2204, Brussels
Site 2102, Kogarah
Site 2202, Leuven
Site 2106, Parkville
Site 2201, Liège
Site 2104, Woodville South
Site 2203, Yvoir
Site 2105, Nedlands
Site 2901, Wellington
Site 2101, Victoria Park
Site 2902, Christchurch
Site 1705, New York
Site 1101, Belgrade
Site 1102, Belgrade
Site 1103, Belgrade
Site 2401, Tallinn
Site 1303, A Coruña
Site 2701, Pieve Emanuele
Site 2703, Milan
Site 2506, Hamburg
Site 1706, Atlanta
Site 2503, Hanover
Site 2704, Udine
Site 1708, Tampa
Site 1703, Sarasota
Site 1302, Santa Cruz de Tenerife
Site 2702, Reggio Emilia
Site 1304, Bilbao
Site 1704, Saint Clair Shores
Site 1707, Lansing
Site 2402, Tartu
Site 2502, Tübingen
Site 2501, Kirchheim unter Teck
Site 2507, Freiburg im Breisgau
Site 2504, Erlangen
Site 1701, Boston
Site 1702, Rochester
Site 2303, Zagreb
Site 2508, Jena
Site 2601, Dublin
Site 2802, Groningen
Site 2801, Rotterdam
Site 1002, Krakow
Site 1301, Barcelona
Site 1604, Edinburgh
Site 1603, Essex
Site 1602, London
Site 1601, Newcastle upon Tyne
Lead Sponsor
Kiniksa Pharmaceuticals, Ltd.
INDUSTRY